Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy

Lerner, D; Dandoy, C; Hirsch, R; Laskin, B; Davies, S M; Jodele, S
June 2014
Bone Marrow Transplantation;Jun2014, Vol. 49 Issue 6, p862
Academic Journal
A letter to the editor is presented regarding pericardial effusion (PEF), which is a complication of hematopoietic stem cells transplantation (HSCT) in pediatric recipients with thrombotic microangiopathy.


Related Articles

  • Early complications following haematopoietic SCT in children. Miano, M.; Faraci, M.; Dini, G.; Bordigoni, P. // Bone Marrow Transplantation;Jun2008 Supplement, Vol. 41, pS39 

    Early complications can be defined as those occurring within 100 days after transplant. Both epithelial and endothelial damage represent the pathogenetic basis for the onset of the most frequent complications. Clinical features related to endothelial damage depend on the involved district or on...

  • The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy. Balassa, K; Andrikovics, H; Remenyi, P; Batai, A; Bors, A; Kiss, K P; Szilvasi, A; Rajczy, K; Inotai, D; Gopcsa, L; Lengyel, L; Barta, A; Reti, M; Tordai, A; Masszi, T // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1321 

    Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT) with high mortality rate. We retrospectively studied the frequency, clinical and genetic associations and prognostic effect of TA-TMA, in a...

  • Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Labrador, J; López-Corral, L; López-Godino, O; Vázquez, L; Cabrero-Calvo, M; Pérez-López, R; Díez-Campelo, M; Sánchez-Guijo, F; Pérez-López, E; Guerrero, C; Alberca, I; del Cañizo, M C; Pérez-Simón, J A; González-Porras, J R; Caballero, D // Bone Marrow Transplantation;May2014, Vol. 49 Issue 5, p684 

    Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the...

  • Thrombotic Microangiopathy in Haematopoietic Stem Cell Transplantation: Diagnosis and Treatment. Choi, Cecilia M.; Schmaier, Alvin H.; Snell, Michael R.; Lazarus, Hillard M. // Drugs;2009, Vol. 69 Issue 2, p183 

    Each year in the US, more than 10 000 patients benefit from allogeneic haematopoietic stem cell transplantation (HSCT), a modality that offers an excellent chance of eradicating malignancy but confers a higher risk of treatment-related mortality. An uncommon but devastating consequence of HSCT...

  • Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation. Sevindik, Ömür Gökmen; Alacacıoğlu, İnci; Katgı, Abdullah; Solmaz, Şerife Medeni; Acar, Celal; Pişkin, Özden; Özcan, Mehmet Ali; Demirkan, Fatih; Ündar, Bülent; Özsan, Güner Hayri // Case Reports in Hematology;1/29/2015, Vol. 2015, p1 

    Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after...

  • Association of Busulfan and Cyclophosphamide Conditioning with Sleep Disorders after Hematopoietic Stem Cell Transplantation. Faulhaber, Gustavo A. M.; Furlanetto, Tania W.; Astigarraga, Claudia C.; Filho, Humberto Luiz Moser; Paludo, Angela Paula; Silla, Lucia M. R. // Acta Haematologica;Oct2010, Vol. 124 Issue 2, p125 

    New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors...

  • Pharmacogenetics of Gemtuzumab-Associated Hepatic Sinusoidal Occlusion Syndrome after Hematopoietic Stem Cell Transplant. Aplenc, Richard; Vachani, Anil; Han, Peggy; Glatfelter, Wendy; Sievers, Eric L. // Acta Haematologica;Dec2003, Vol. 110 Issue 4, p207 

    Presents a study that investigated the pharmacogenetics of Gemtuzumab-associated hepatic sinusoidal occlusion syndrome (SOS) after hematopoietic stem cell transplant (HSCT). Variable risk of SOS development in patients exposed to gemtuzumab after HSCT; Analysis of reactive oxygen species...

  • A phase II study of sirolimus, tacrolimus and rabbit anti-thymocyte globulin as GVHD prophylaxis after unrelated-donor PBSC transplant. Khaled, S K; Palmer, J; Stiller, T; Senitzer, D; Maegawa, R; Rodriguez, R; Parker, P M; Nademanee, A; Cai, J-L; Snyder, D S; Karanes, C; Osorio, E; Thomas, S H; Forman, S J; Nakamura, R // Bone Marrow Transplantation;Feb2013, Vol. 48 Issue 2, p278 

    We report on a prospective phase II trial of 32 patients who underwent unrelated-donor hematopoietic cell transplantation, with a tacrolimus, sirolimus and rabbit anti-thymoctye globulin GVHD prophylactic regimen. The primary study endpoint was incidence of grades II-IV acute (aGVHD), with 80%...

  • HY Immune Tolerance Is Common in Women without Male Offspring. Dierselhuis, Miranda P.; Jankowska-Gan, Ewa; Blokland, Els; Pool, Jos; Burlingham, William J.; van Halteren, Astrid G. S.; Goulmy, Els // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Sex difference is an established risk factor for hematopoietic stem cell transplantation (HSCT)-related complications like graft versus host disease (GVHD). CD8pos cytotoxic T cells specific for Y chromosome-encoded minor Histocompatibility antigens (HY) play an important role...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics